KMTS vs AMAT vs LRCX vs MDT vs ABT

For growth investors, KESTRA MEDICAL TECHNOLOGIES, LTD.

(KMTS) is the stronger pick with 115. 1% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Abbott Laboratories (ABT) offers the better valuation at 11. 4x trailing P/E (15. 9x forward), making it the more compelling value choice. Analysts rate KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

4x versus Lam Research Corporation at 69. 0x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 53x versus Medtronic plc's 36. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Lam Research Corporation (LRCX) delivered a total return of +360.

5%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: LRCX returned +38. 2% versus KMTS's -1. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus Lam Research Corporation's 2. 54β — meaning LRCX is approximately 924% more volatile than ABT relative to the S&P 500. On balance sheet safety, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a lower debt/equity ratio of 22% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), KESTRA MEDICAL TECHNOLOGIES, LTD.

(KMTS) is pulling ahead at 115. 1% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -151. 5% for KESTRA MEDICAL TECHNOLOGIES, LTD.. Over a 3-year CAGR, AMAT leads at 3. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -190. 3% for KESTRA MEDICAL TECHNOLOGIES, LTD. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LRCX leads at 32. 0% versus -177. 8% for KMTS. At the gross margin level — before operating expenses — MDT leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 53x versus Medtronic plc's 36. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 50. 7x for Lam Research Corporation — 36. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABT: 47. 9% to $128. 71.

All stocks in this comparison pay dividends.

Medtronic plc (MDT) offers the highest yield at 3. 6%, versus 0. 2% for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). Applied Materials, Inc. (AMAT) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, AMAT: +20. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KMTS (Healthcare) and AMAT (Technology) and LRCX (Technology) and MDT (Healthcare) and ABT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KMTS is a small-cap high-growth stock; AMAT is a large-cap quality compounder stock; LRCX is a large-cap high-growth stock; MDT is a mid-cap income-oriented stock; ABT is a mid-cap deep-value stock. MDT, ABT pay a dividend while KMTS, AMAT, LRCX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.